Clinical trials: Liraglutide
Impaired Glucose Tolerance Associated With Drugs
Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among antipsychotic-treated patients.
- Trial name
- GREAT (NCT01845259)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Psychiatric Centre Rigshospitalet
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Diabetic Kidney Disease (DKD), Type 2 Diabetes
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
We are conducting this clinical trial to find out whether Guominkang-a traditional Chinese herbal formula-is safe and effective for people with diabetic kidney disease (DKD).
- Conditions
- Diabetic Kidney Disease (DKD), Type 2 Diabetes, Albuminuria
- Trial name
- NCT07907965
- Testing
- Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing University of Chinese Medicine
Type 2 Diabetes Mellitus
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
- Trial name
- NCT01558271
- Testing
- LY2189265, Liraglutide
- Where
- 14 sites in Japan
- Volunteers
- 492 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes (T2DM)
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people.
- Trial name
- Beta (NCT07325435)
- Testing
- SGLT-2 inhibitor, GLP1-RA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MaryAnn Banerji
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Heart Frequency in Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if liraglutide effects the QTc interval. Moxifloxacin (Avelox®) is administered as positive control.
- Trial name
- NCT01516255
- Testing
- liraglutide, moxifloxacin, electrocardiogram (ECG)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide (formulation 4) and the liraglutide formulation planned for phase 3b trials (final formulation 4).
- Trial name
- NCT01515553
- Testing
- liraglutide
- Where
- Sweden
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Obesity, PreDiabetes
Cardiovascular Effects of GLP-1 Receptor Activation
This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that…
- Trial name
- NCT03101930
- Testing
- Liraglutide, Sitagliptin, hypocaloric diet
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Vanderbilt University Medical Center
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.
- Trial name
- NCT02527200
- Testing
- liraglutide
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes
This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.
- Trial name
- NCT01511692
- Testing
- liraglutide, glimepiride
- Where
- 2 sites in Australia, Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight…
- Trial name
- NCT01029886
- Testing
- exenatide once weekly, liraglutide
- Where
- 108 sites in Argentina, Australia and 19 more
- Volunteers
- 912 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it…
- Trial name
- NCT04373967
- Testing
- Victoza®., Metformin Hydrochloride, TQZ2451
- Where
- 46 sites in China
- Volunteers
- 424 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Healthy
Liraglutide Effects on Memory in Healthy Subjects
This study examines the hypothesis, that subcutaneous administration of liraglutide, an analogue of the incretin glucagon-like peptide 1, over 5 weeks improves memory functions in healthy humans.
- Trial name
- NCT01550653
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Luebeck
Severe Obesity, Cardiovascular Function
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity
This randomized controlled trial evaluates the efficacy, safety, metabolic, and cardiovascular effects of liraglutide in children aged 6 to 12 years with severe obesity.
- Conditions
- Severe Obesity, Cardiovascular Function, Liraglutide, Childhood Obesity
- Trial name
- NCT07590219
- Testing
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo General Hospital
Metabolism and Nutrition Disorder, Obesity
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for…
- Trial name
- NCT02870231
- Testing
- NNC9204-0530, liraglutide
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Novo Nordisk A/S
Obesity
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers.
- Trial name
- NCT07640139
- Testing
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Where
- United States
- Volunteers
- 125,000 people
- Sponsor
- Indiana University
Weight Loss
Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients
Investigators postulate that the metabolic effects of LSG would be augmented with the use of liraglutide leading to additional excess weight loss, improved glucose homeostasis, decreased intrapancreatic and intrahepatic fat than…
- Trial name
- NCT04325581
- Testing
- Liraglutide 6 MG/ML
- Volunteers
- 16 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liraglutide Blood-brain Transfer
Liraglutide in Spinal Fluid
The purpose of this study is to investigate transfer of liraglutide from blood to cerebrospinal fluid.
- Trial name
- LIRA-CSV (NCT02104037)
- Testing
- Lumbar puncture
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Mikkel Christensen
Healthy
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the pharmacokinetics of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared with Xultophy®.
- Trial name
- NCT06449703
- Testing
- insulin degludec/liraglutide, Xultophy®
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd